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Aggregation analysisExpression of recombinant proteins in Escherichia coli (E. coli) remains the most popular and cost-
effective method for producing proteins in basic research and for pharmaceutical applications.
Despite accumulating experience and methodologies developed over the years, production of
recombinant proteins prone to aggregate in E. coli-based systems poses a major challenge in most
research applications. The challenge of manufacturing these proteins for pharmaceutical applica-
tions is even greater. This review will discuss effective methods to reduce and even prevent the for-
mation of aggregates in the course of recombinant protein production. We will focus on important
steps along the production path, which include cloning, expression, puriﬁcation, concentration, and
storage.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Aggregation is a complex process that originates by several dif-
ferent mechanisms [1–3]. Aggregates can be formed from self-
association of the native conformation, or by structurally altered
states. Aggregation can be typically induced by nucleation of a
few proteins, which form small and soluble aggregates; these then
serve as nucleation foci for the subsequent growth of larger insol-
uble aggregates. The nucleation-growth process can increase with
time, temperature, protein concentration, and other parameters.
Importantly, an extended lag phase can abruptly precede the for-
mation of the large insoluble aggregates [1].
The intrinsic properties of proteins could be responsible for
mediating the aggregation step when expressed in E. coli. One
major example is the family of intrinsically disordered proteins
(IDPs) and intrinsically disordered regions (IDRs) that belong to a
large family of proteins possessing amino acid regions that lack a
stable tertiary structure [4,5]. Their dynamic and ﬂexible confor-
mations readily tend to aggregate.However, the intrinsic properties of proteins are not the sole
factors contributing to the tendency of heterologous proteins to
form aggregates. Factors related to the expression and to the puri-
ﬁcation conditions can play an important role in the misfolding of
proteins. At the expression level, incompatibility of the bacterial
machineries to fold proteins of eukaryotic origin, which include
coupled transcription-translation mechanisms, the lack of suitable
chaperones and post-translational modiﬁcations, as well as the ab-
sence of compartmentalization, may also contribute to the aggre-
gation process. At the puriﬁcation level, the physicochemical
conditions surrounding of the protein, concentration and many
others factors greatly inﬂuence folding. Numerous strategies have
been developed to minimize protein aggregation and enhance their
solubility. These include the following:(i) Developing procedures
to tightly control the expression of the proteins using specialized
promoters; (ii) Attaching the protein to solubility-enhancing fusion
proteins; (iii) Developing specialized bacterial host strains; (iv)
Screening for speciﬁc growth and induction conditions; (v) Consid-
ering practical methods to reduce aggregation during the puriﬁca-
tion steps; and (vi) Screening for suitable buffer conditions for
protein puriﬁcation.
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methods singly. However, we believe that developing a strategy
that combines and integrates the optimization of all these methods
simultaneously will maximize the potential of soluble protein
production.2. Factors that inﬂuence aggregation during the expression
stage
2.1. Expression vectors
2.1.1. Choice of promoters
The ﬁrst steps for successful expression of soluble protein start
with cloning of the target gene into an expression vector contain-
ing a tightly regulated promoter. Tight regulation of transcription
allows the expression to be carried out in a controlled environ-
ment, enabling not only the production of the target protein under
optimal conditions, but also improvement of reproducibility and
easier scale-up of the production conditions. This regulation can
be further improved when the expression vector contains an origin
of replication with low-copy number. One of the most popular sys-
tems used in numerous research and pharmaceutical applications
are the T7-promoter-based vectors (commercially available from
companies such as BD Novagen, NEB, and Invitrogen). These
expression vectors contain a T7 promoter that is not recognized
by the cellular RNA polymerase; therefore, they prevent leaky
expression in strains that do not contain an exogenous T7 RNA
polymerase gene. Specialized expression strains were developed
for these systems, containing a chromosomal copy of the T7 RNA
polymerase gene (DE3) under various promoters [6]. Inducing
the expression of the T7 RNA polymerase results in the subsequent
induction of a target gene cloned under the T7 promoter. This sys-
tem has a large variety of vectors and host strains for various uses
that will be discussed in detail in the following sections. Other
tightly regulated vectors contain promoters such as the araC pro-
moter, induced by arabinose [7], and the cspA promoter, induced
by a temperature shift to 15 C in the pCold vectors manufactured
by TAKARA [8]. Cloning the target gene under such tightly regu-
lated promoters allows screening under various environmental
conditions and identiﬁcation of the exact and reproducible condi-
tions needed for enhancing protein solubility. Despite the obvious
advantage of using powerful promoters that may lead to product
accumulation of up to 30% of the total cellular protein, over expres-
sion can often drive the protein towards aggregation. In some cases
there is an advantage in using promoter that can be ﬁne-tuned,
such as the araC, or even weak promoters such as the lac promoter,
which allows a slower accumulation of correctly, folded proteins.
There are cased in which best results can be obtained without
induction, with only low levels of leaky expression accommodate
optimized conditions for soluble protein production. However, this
strategy is sometimes difﬁcult to scale up due to variation in media
formulations. In conclusion, the ability to control expression levels
is a key element in the choice of bacterial expression vectors [9,10].
2.1.2. Choice of fusion proteins
Fusion proteins have the best success rate in improving the sol-
ubility of target proteins in Escherichia coli [11], and are often uti-
lized to simplify the isolation using either their intrinsic properties,
or an additional small afﬁnity tag. However, it is difﬁcult to accu-
rately predict the effect of the various fusion partners on the solu-
bility and expression proﬁle of speciﬁc targets [11–13]. Therefore,
it is often necessary to screen a battery of fusion constructs to
determine which is most suitable. Despite the advantage of parallel
screening of a large collection of tags, in recent years many protein
production facilities have reduced this intensive screening to aselected few favorable fusion tags, thus avoiding massive high
throughput screening (HTS) platforms, by matching the fusion pro-
tein’s qualities to the requirements of the target protein partner.
Among the more popular solubility-enhancing fusion proteins are
the maltose-binding protein (MBP) [14]; thioredoxin (TrxA) [15];
nutilization substance A (NusA) [16]; small ubiquitin-related mod-
iﬁer (SUMO) [17,18], gluthatione S-transferase (GST), and several
hyper-acidic short protein fusion tags [19].
MBP is the most studied solubility enhancer, and accumulating
evidence suggests that it serves as a passive participant in the fold-
ing process; it acts as a stabilizer of partially folded target proteins,
until spontaneous or chaperone-mediated folding occurs [20]. De-
spite MBP’s considerable size (44 kDa), its high expression level,
combined with its efﬁcient puriﬁcation options (dextrin Agarose
columns or IMAC chromatography when a His-tag is added to
the N-terminus), makes it a suitable candidate for solving a wide
range of aggregation problems, and it should be included in most
fusion-protein expression screens [21]. MBP is suitable for tagging
relatively smaller proteins (up to around 40 kDa) because the bac-
terial machinery is less efﬁcient when large proteins (over 90 kDa)
are produced, and this tends to result in low productivity and par-
tially truncated protein forms.
Another large fusion protein that facilitates solubility similarly
to MBP is NusA, a 55 kDa protein, highly soluble in E. coli [22].
Although this protein enhances the solubility of target proteins,
sometimes with a higher efﬁciency than MBP, its large size and
tendency to adhere to the target protein after attempts to cleave
off the tag constitute a considerable disadvantage. An additional
noteworthy fusion partner is the SUMO protein. It has solubility
enhancement effects similar to MBP, and is gaining popularity ow-
ing to its accumulating successful results, its small size, and an efﬁ-
cient and highly speciﬁc tag-removal procedure with SUMO
protease. The TrxA protein, which is about 11 kDa in size, can be
used with larger target proteins, but it is most suitable for enhanc-
ing the solubility of proteins that contain disulﬁde bonds [23]. GST
has been one of the most traditional tags used for many years, for
over-expression and enhanced solubility. In recent years it has
mainly been used as a popular tag for pull-down assays and pro-
tein–protein interaction studies. However, despite its great advan-
tage in these applications, according to our personal experience
and that of other protein production laboratories participating in
the Protein Production and Puriﬁcation Partnership in Europe
(P4EU), GST seldom contributes to the solubility of its fused target
protein in E. coli, and can cause pre-mature termination of the
polypeptide chain, or even enhance aggregation, owing to its di-
meric form.
Other solubility enhancers, like acidic fusion partners, act as
‘‘electrostatic shields’’, reducing the probability of aggregation via
electrostatic repulsion between highly charged soluble polypep-
tide, thus allowing adequate time for correct folding. In addition,
these solubility enhancers might directly act as intramolecular
chaperones by participating in native folding of the target proteins
[19]. This family of fusion proteins includes the lipoyl domain from
B. Stearothermophilus E2p [24], consisting of a short acidic 109 ami-
no acid tag (pI: 4.53 and MW: 11994.3 Da). The lipoyl domain fu-
sion tag containing the N-terminus His tag and an optimized
Tobacco Etch Virus (TEV) protease cleavage site (termed HLT-tag)
is used at our facility as the preferable fusion protein for enhancing
the solubility of IDR proteins [25–27]. This tag is best suited for
NMR studies and is highly resistant to proteases (received from
Dr. Mark Allen: MRC-CPE, Cambridge, England).
Other noteworthy fusion partners are the N-Domain of E. coli
phosphoglycerate kinase, a 22 kDa protein domain, recently re-
ported by the Lee group to enhance solubility of several prone-
to-aggregate proteins [28], and two additional tags: the modiﬁed
bacteriophage T7 protein kinase and the E. coli Skp chaperone,
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combination with several prone-to-aggregate targets, and exhib-
ited enhanced solubility of the target proteins even after cleavage
of the fusion tags. There are additional fusion proteins that may
support solubility in disulﬁde bond-containing proteins, such as
DsbA [12,30], which is used for periplasmic secretion and cytosolic
expression, and the DsbC tag, which facilitates disulﬁde bond for-
mation [31]. These options and many others should be considered
either in a HTS format or for research projects requiring speciﬁc
protein characteristics.
Fusion proteins and tags often have to be removed from the tar-
get protein owing to their potential tendency to interfere with
downstream applications. Hence, efﬁcient removal of the tags
plays an important role in their selection [32]. Proteases such as
thrombin and factor Xa have traditionally been used for many
years; however, in recent years these proteases have been replaced
by more speciﬁc, stable, and easy-to-produce proteases that are ac-
tive at low temperatures. These proteases include the Tobacco Etch
Virus (TEV), Rhinovirus 3C Protease (i.e. PreScission™), SUMO pro-
tease (which speciﬁcally recognizes SUMO protein), and enteroki-
nase. Comprehensive reviews on proteases can be found in [32–
35].
Despite the obvious advantages of using fusion proteins, three
main drawbacks must be emphasized: (1) pharmaceutical compa-
nies are often reluctant to use them, due to the high cost of the tag
removal process, and the extended puriﬁcation steps needed to
avoid the risk of contaminating the protein preparations with a
partially cleaved product. (2) Most of the proteases leave a few
additional amino acids at the N-terminus of the fused protein after
cleavage. This may interfere with protein activity, immunogenicity,
and other properties. (3) The main drawback of cleaving of fusion
proteins is that cleavage is often followed by loss of solubility of
the target protein. Circumventing this last drawback will be dis-
cussed in section 3 of this review.
2.1.3. Gene cloning
In recent years, improvements in technology have enabled cost-
effective production of synthetic genes, and consequently, ordering
codon-optimized genes for heterologous expression in E. coli has
become a standard practice. Codon-optimized genes often increase
the production levels and may also prevent premature termination
of the elongated polypeptide [36]. Nevertheless, rare codons play a
crucial role in regulating protein production and in protein folding
[37]. Hence, we postulate that the use of codon-optimized genes
might sometimes result in proteins that are more likely to aggre-
gate. Although there is still no direct evidence to support this spec-
ulation with regard to genes expressing in E. coli, it might be
worthwhile to consider these variables when developing future co-
don optimization algorithms.
Taking all this into consideration, we believe that the beneﬁts of
using synthetic codon-optimized genes outweighs their draw-
backs, and enable a simple and efﬁcient cloning method for most
genes, which simpliﬁes the cloning of complex and custom-de-
signed constructs.
Another strategy employed when attempting to express a large
multi-domain protein is to design a series of truncations to pro-
duce smaller, single domains that are easier to express in a soluble
form. This can be achieved by designing primers to amplify speciﬁc
domain boundaries and by expressing multiple domains in cell-
free arrays or in parallel, cloning them into expression vectors. This
strategy can be employed mainly for HTS platforms, and it is most
beneﬁcial when combined with an enzymatic activity assay that
can detect active domains in a HTS platform. In some cases, struc-
tural and molecular displacement data may allow small-scale
screening of rationally designed domains. When no structural data
are available, there are several on-line tools for predicting solubledomains. However, the precise domain boundaries can vary,
depending on the prediction method used [38]. Domain selection
has limited uses; it increases the screening cost, and can be em-
ployed only when smaller domains are suitable for the required
applications.
2.2. Bacterial host strains
Parallel screening of expression in various bacterial strains can
often result in enhanced solubility in speciﬁc strains. Sometimes
for reasons that are not completely understood, screening of
expression in BL21-based strains and K12-based strains may yield
a completely different solubility proﬁle of the same protein. How-
ever, as in the case of selecting suitable fusion partners, HTS plat-
forms are not always an available option, and therefore carefully
selecting a small number of host strains may be sufﬁcient to design
an efﬁcient screening procedure.
As in the case of tightly regulated promoters, there are consid-
erable advantages of using strains that support tight regulation of
induction and that prevent leakiness. Good examples of such
strains are those that contain a chromosomal copy of the T7 RNA
polymerase gene cloned downstream from a regulated promoter.
These include strains such as BL21AI (Invitrogen), in which the
induction of the T7 RNA polymerase is controlled by arabinose,
and where leakage of the target protein is suppressed until suitable
conditions are achieved in the culture. Other available host strains
were created by mutating the lac permease (lacY) gene to allow
uniform entry of IPTG into all cells. This produces linear concentra-
tion-dependent induction and enables one to maintain low con-
centrations of an inducer throughout the induction process (such
as Tuner™ from Novagen). These specialized strains, which allow
better control over environmental and internal conditions, increase
the chances of enhancing solubility by reducing the translation
rate and allowing proper folding of the protein in the bacterial cou-
pled transcription-translation mechanism. However, there are
cases when these changes are still insufﬁcient for large-scale pro-
duction of proteins that are prone to aggregate.
Several bacterial strains were developed to address the speciﬁc
characteristics of aggregating proteins. The C41(DE3) and
C43(DE3) strains, with proliferated intracellular membrane, were
originally isolated by the Walker group [39] and were found to
support higher production of active membrane proteins. A more
recently developed strain, Lemo21 (DE3), contains mutations in
the lacUV5 promoter governing the expression of T7 RNA polymer-
ase [40–42], which was also designed to enhance the expression of
active membrane proteins. Although this review does not directly
address the aggregation of membrane proteins, our experience
shows that these commercial strains (available from Lucigen and
NEB) can successfully be utilized to enhance the solubility of not
only membrane proteins but also hydrophobic and IDR proteins.
One of the most prominent causes for the formation of protein
aggregation and inclusion bodies is the reducing environment in
the cytosol, which does not allow the formation of disulﬁde bonds.
One option to facilitate the correct formation of disulﬁde bonds is
to secrete the protein to the periplasmic space; however, this will
often result in a dramatic decrease in productivity. Specialized
strains with impaired activity of the thioredoxin reductase (trxB)
and glutathion reductas (gor) genes allow diminishing of the
reductive pathways, and can support the formation of disulﬁde
bonds in the cytosol [43–45]. These strains are commercially avail-
able from Novagen (Origami™). However, even in these strains the
ratio between properly modiﬁed protein and aggregated protein is
still low, especially under over-expression conditions. In a recent
study [46], researchers demonstrated that adding a chromosomal
copy of the disulﬁde bond isomerase, DsbC, which lacks its native
signal sequence, facilitates achieving higher efﬁciency of disulﬁde
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nant protein. This strain is currently commercially available from
NEB. It is important to emphasize that most therapeutic proteins
contain disulﬁde bonds [44]; hence, there is a growing need to de-
velop more robust bacterial hosts that allow over-expression of
correctly folded target proteins.
2.3. Expression conditions
Expression conditions and regulated induction play a crucial
role in preventing aggregates during the production stage. The
expression conditions consist of the following: induction temper-
ature, induction duration, inducer concentration, and media for-
mulation. Changes in the induction temperature may inﬂuence
the elongation rate of the polypeptide chain, consequently induc-
ing the collapse of the elongating polypeptide chain into ordered
structural domains. Reducing the induction temperature often has
a positive effect on the solubility, attributed to the slower elonga-
tion of the polypeptide chain. Slowing down this step allows bac-
terial chaperones and chemical additives to protect the elongated
chain and it supports correct folding [47,48]. Inducer concentra-
tion affects the mRNA production and inﬂuences the local con-
centration of elongated polypeptide chains. Reduced
concentrations of the inducer may prevent aggregation of the
growing chains while they are still on the polysome. In addition,
osmolyte chemical chaperones such as glycerol, proline, and sor-
bitol, when added in small concentrations to the growth media,
may further impede the process, enabling a better-suited micro
environment for proper folding during the peptide elongation
step[49,50] [51].
2.3.1. Auto-inducing media
Traditional expression screens include parallel use of various
media formulations differing in peptone concentration, yeast ex-
tract, and salts. In recent years, development of media formula-
tions for auto-induced expression has proved to have a dramatic
inﬂuence on protein production in general and on soluble product
in particular. Auto-inducing formulations are based on the well-
studied mechanism by which glucose suppresses induction by lac-
tose. Together with metabolic balancing of pH and additional fac-
tors, specialized media were developed that allow reliable
suppression and auto-induction of proteins of high density in bac-
terial cultures. The autoinduced media formulations are mostly
compatible with T7-based expression systems, but they can also
be adapted for arabinose induction and used with an extended
range of bacterial expression systems [52]. These formulations al-
low parallel screening of numerous factors in combination with
various media formulations, based on a simple inoculation proce-
dure, and allow this media to be compatible for both large-scale
HTS screening and for more limited screening platforms.
2.3.2. Screening media components
Including different media formulations in expression screens is
a simple and often beneﬁcial manipulation, although it is difﬁcult
to predict which formulation (whether the higher or lower nutri-
ent concentration) will improve the expression levels and solubil-
ity of a target protein. A promising aspect of media formulation is
currently under research in our laboratory: exploring the potential
of speciﬁc Saccharomyces cereviciae peptones and yeast extract
combinations, such as the Springer

yeast extract and yeast pep-
tones to enhance the production of soluble proteins. It is difﬁcult
to predict which formulation combination will result in enhanced
solubility; however, screening these extracts in combinations in an
auto-inducing media resulted in enhancement of soluble protein
production compared to conventional media formulations
(unpublished data).2.3.3. Induction and co-expression with chaperones
A general strategy to improve the native folding and solubility
of recombinant proteins is to increase the cellular concentration
of chaperones in the vicinity of the elongated polypeptide chain.
There are two ways to achieve this: one is by treating bacterial
growth with ‘‘heat-shock’’ prior to induction, to stimulate the pro-
duction of heat-shock chaperones. This is usually done in our lab-
oratory, combined with a low concentration of chemical
chaperones: glycerol, potassium glutamate and benzyl alcohol,
that elevates the cellular concentration of these viscous osmolytes,
and enhances the effect [49,50]. Another more controlled method-
ology is to express with speciﬁc chaperones, for example: DsbA
and DsbC, to promote disulﬁde bond formation in cytomlasmic
or periplasmic space [53,54]. This strategy can also be combined
with the addition of osmolytes. When lacking speciﬁc knowledge
of suitable chaperones, screens for expression in the presence of
combinations of chaperones can be conducted [55]. A comprehen-
sive review examining the advantages and disadvantages of this
approach can be found in a review by Kolaj et al. [56].
2.4. A combined approach for screening under solubility-enhancing
expression conditions
As described in chapters 2.1 – 2.3, there are numerous vectors,
bacterial strains, and environmental conditions that can be tested
in order to determine the conditions for improving protein solubil-
ity. Many but not all parameters can be screened using HTS plat-
forms. Some procedures, such as using unique expression
systems and induction methodologies, should be carried out indi-
vidually, in cases where the HTS format is not suitable or is too
laborious. Most research laboratories focus on a single target, or
targets from the same family of proteins. For this type of project
we have developed a simple and cost-effective screen described
in Flow chart 1. In this screen, the features of the individual target
are ﬁrst analyzed using databases and on-line bioinformatics tools.
This ﬁrst step will determine the choice of one or two fusion part-
ners that will be attached to the N-terminus of the protein, in a T7
promoter-based vector. For example, if the protein contains IDRs,
we will construct the gene with an N-terminus HLT tag and either
a His-MBP or His-SUMO, depending on the size of the protein (i.e.
proteins smaller than 40 kDa will be attached to MBP, whereas lar-
ger proteins will be attached to SUMO). We will then decide on
several appropriate bacterial strains. Here, the standard BL21(DE3)
and HMS174(DE3) strains should be added to the C41(DE3) and
C43(DE3) strains. Parameters for selection of fusion partners and
host strains are presented in Table 1. We usually transform two
constructs into four host strains, inoculate single colonies into an
auto-induced media array for 16 h at two different temperatures
(usually 37 and 30 C), lyse the samples, load on batch IMAC, and
then analyze elutions by SDS–PAGE using Coomassie staining and
Western blots. This procedure usually takes two days and enables
one to select the best combination of fusion protein and expression
strain. Additional parameters such as longer induction times, lower
temperatures, and various media formulations can be added in the
same platform. After selecting the most promising construct-host
strain combination, we proceed by reﬁning the screening to test
the effect of inducer concentration, temperature, and induction
duration. Batch IMAC elutions are analyzed by SDS–PAGE as in
the ﬁrst screening. The most efﬁcient combination will be scaled
up to medium scale growth (50–100 ml) and analyzed on IMAC
and on analytical Gel Filtration (GF). This process covers the most
inﬂuential expression aspects of protein solubility in less than a
week from obtaining the cloned constructs (Flow chart 1).
This simple and modular screen follows the ‘‘20/80 rule’’, i.e.,
achieving 80% of the beneﬁts with only 20% of the resources, while
addressing the majority of solubility problems. It can easily be
Scale-up selected condions and analyze on IMAC and analycal GF (Flowchart 2)
Second round of opmizaon with selected strains****
Isolate  soluble protein on batch IMAC and analyze by Coomassie staining and 
Western blot***
Screen expression condions in auto-induced media at 25, 30 and 37 C 
Transform to 3-5 selected bacterial strains **
Clone with 1-2 suitable fusion proteins containing His Tag 
Diagnose possible reasons for aggregaon *
Flow chart 1. Screening methodology for expressing prone-to-aggregate proteins ⁄According to the literature, bioinformatics data analysis. ⁄⁄According to the requirements
of the target protein, for example: expected disulﬁde bonds will include Shufﬂe and Origami strains in addition to standard strains such as BL21 (DE3) and HMS174.
⁄⁄⁄Coomassie staining allows semi-quantitative estimation of yield whereas Western blot analysis allows the detection of truncated and degraded byproducts. ⁄⁄⁄⁄Screening
using various inducer concentrations, temperatures, induction durations, and media formulation (heat shock: if required).
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subsequent procedures for isolation and concentration, it proved to
be extremely efﬁcient for the vast majority of IDR, IDP, and other
types of proteins prone to aggregate that were tested at our facility
over the years [25–27,57–59].
3. Factors that inﬂuence protein aggregation during
puriﬁcation
Although protein solubility during expression is an essential
prerequisite, aggregation problems can often arise at later stages
during the puriﬁcation process.
It is often tempting to try to solve solubility problems by
decreasing protein concentration or by changing pH or salt concen-
trations. These simple solutions may dissociate the aggregates in
cases where molecules are held together by relatively weak, non-
covalent interactions. pH- or salt-dependent reversibility is indica-
tive of equilibrium between the monomer and high-order forms
[60]. However, such changes rarely affect most types of aggrega-
tion and we discuss here a more comprehensive approach that
should be taken to deal with protein aggregation.
3.1. General issues
There are many protein stability issues that must be addressed
starting at the very early puriﬁcation steps until ﬁnal storage. As
can be seen in Table 2, there are general issues to consider: low
puriﬁcation times, low temperatures of puriﬁcation, low protein
concentrations at each step, prevention of mechanical or non-
mechanical stresses (freezing, exposure to air, interactions with
metal surfaces, etc.) and others.3.1.1. Avoid high protein concentrations
A source of aggregation problems during processing could be
the high protein concentration during different puriﬁcation steps
such as:
(1) The lysis step: this can be solved by using a higher ratio of
lysis buffer to cell paste.
(2) Protein crowding at the top of the column during chromato-
graphic loading: this can be solved by using a batch proce-
dure or using an excess of resin.
(3) High protein concentration during elution: dilute proteins
by adding buffer to collection tubes, or immediately after
elution exchange the buffer by dialysis or buffer exchange
columns.
(4) During concentrations: before any protein concentration
optimize the buffer composition and procedure to be used
before any protein concentration.
3.1.2. Work at low temperatures - Early elimination of protein
aggregates
There is a possibility that the presence of soluble aggregates
after the ﬁrst IMAC column will trigger the insolubility of more
protein molecules and decrease the total yield (unpublished
data). Therefore, important points for prone-to-aggregate proteins
are (a) Slow aggregation process by working at low temperatures.
(b) Remove soluble aggregates as soon as possible by performing
size exclusion chromatography (SEC) immediately after the IMAC
puriﬁcation and before tag cleavage (instead of the common
strategy described by [22,33], where recombinant protein is ﬁrst
cleaved during dialysis, followed by negative IMAC and ﬁnal pol-
ishing SEC).
Table 1
Common reasons for aggregation and the way to address them during the expression procedures.
A B C D E
Cause of aggregations Vector Host Strain Growth conditions* Refs.
Lack of correct disulﬁde bond
formation
Fuse with TRX, DsbA, and DsbC fusion
partners. Clone with periplasmic secretion
signals (pelB, OmpA)
Use Origami and Shufﬂe strains
for cytosolic expression
Standard screen [44–46]
Intrinsically disordered
protein
Fuse with MBP, Sumo, and lipoyl-domain
tag
Membrane-rich strains such as
C41 and C43
Standard screen
Heat shock with chemical
chaperones
[25–27]
Hydrophobic protein Fuse with solubility-enhancing proteins
such as MBP, and SUMO
Membrane-rich strains such as
C41 and C43
Standard screen
Heat shock with chemical
chaperones
[14,21]
No appropriate chaperones Co-express with chaperone-containing
vectors
Screen various BL21 and K12
strains
Standard screen
Heat shock with chemical
chaperones
[49–51,54]
Protein is natively directed to
a sub-cellular localization
Remove the localization signal or replace
the signal with a periplasmic secretion
signal (pelB, OmpA)
Membrane-rich strains such as
C41 and C43 or Lemo strain
Standard screen
Reduce inducer concentration
Induce at a high OD
[41]
Membrane protein Generate and screen soluble domains Use membrane-rich strains such
as C41 and C43, or Lemo strain
Lower the induction temperature
Reduce the inducer concentration
Induce at a high OD
[41,42]
Protein is part of a complex Fuse with large fusion proteins such as
MBP. NusA co-expresses with a partner: a
combination of 2–4 vectors for max 8
proteins
Screen tight induction-regulated
strains
Heat shock with chemical
chaperones
[49,50]
Column A speciﬁes a list of reasons that can lead to protein misfolding during the expression steps. Columns B and C state changes in the parameters in the expression vector
and the host cells, respectively. Column D describes various growth conditions, where ‘‘a standard screen’’ refers to the screening of variables such as temperature, the
duration of induction, screening of various inducer concentrations, and screening of various media formulations. Each of the sections can be changed separately, or combined
together with the others.
* Our standard heat-shock procedure involves the addition of 0.1% glycerol and 0.1 mM potassium glutamate. Detailed procedures for both standard screens and heat-shock
procedures can be found in the following link: http://wolfson.huji.ac.il/expression/procedures/bacterial/Induction.Condition.Callib.new.htm.
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Since the process time is one of the most critical points to con-
sider, great emphasis must be given to designing a ‘‘quick strategy
of puriﬁcation’’, where pure protein must be produced and stored
as fast as possible. To achieve this goal, intensive work must be car-
ried out to optimize and ﬁne-tune each puriﬁcation step before
scale-up. This will guarantee that the whole process can be
achieved swiftly and smoothly.
3.2. Protein environmental issues
In addition to the general considerations, there are speciﬁc con-
siderations involving environmental buffers: pH, ionic strength,
cosolutes such as chaotropes and kosmotropes, osmolites and li-
gands, reducing agents, surfactants, and non-denaturative deter-
gents (Table 2). Although many recommended additives are
found in the literature, the type and optimal range for each protein
is highly speciﬁc and the speciﬁc conditions must be ﬁne-tuned for
each project (Table 3). These environmental factors can either act
by stabilizing proteins or by inhibiting aggregation and protein–
protein interactions [61,62].
Owing to the difﬁculty of predicting the efﬁciency of each of
these factors, the logical option is to test a big matrix of different
buffers at diverse pHs and conductivities in the presence of differ-
ent additives like those presented in Table 3. Leibly et al., using a
screening methodology with 144 conditions, showed in a recent
publication that only the classical ones give the best results: treha-
lose, glycine betaine, mannitol, L-arginine, potassium citrate, CuCl2,
proline, xylitol, NDSB 201, CTAB, and K2PO4 [63]. This conﬁrms our
experience that short lists of additives, tackling insolubility by dif-
ferent ways, and covering most of the aggregation mechanisms,
considerably reduce costs and efforts. A similar short list and hier-
archical approach of relevant buffer selection has been previously
reported by the Bondos lab [61,64], where the ﬁrst step is testing
additives in each category, which is followed by a second screening
of similar additives from the same family.3.3. Methods for monitoring protein aggregates
Various experimental methods are routinely used to check
aggregation. The initial step in most approaches is to test the pro-
tein sample using a combination of different buffers and additives
(Table 3), and to incubate the reaction overnight at 4 C (or under
optional incubation conditions). These different screens can be
used on puriﬁed or partially puriﬁed protein samples and analyzed
using several methods.
Functional biological assays can be used when the target pro-
tein can be tested in a simple activity assay. However, this ap-
proach is not suitable for most proteins since such assays are not
always available. However, most importantly, activity assays do
not provide information regarding yield, oligomeric homogeneity,
and protein purity.
Other simple methods such as visual observation of turbidity
under a microscope [65] optical density at different wavelengths
(340, 490, or 600 nm), turbidimetry, and analyzing spin-ﬁltered
samples on PAGE–SDS, although simple to perform, identify only
big massive aggregates and cannot detect soluble aggregates. A ﬁl-
ter-based aggregation assay using ultraﬁltration devices was
developed to identify soluble aggregates based on the MW cut-
off of the monomer protein [64]. However, this approach is not
very reliable and many artifacts can affect the ﬁnal results.
Instruments such as circular dicroism (CD), light scattering (LS),
and very accurate analytical ultracentrifugation (with low sample
throughput) can identify the presence of soluble aggregates; how-
ever, these instruments are not always available in many laborato-
ries, and the results are often not easily interpreted. Moreover, CD
is incompatiblewithUVactive substances that canbe found inmany
buffers, while LS cannot always detect monomers in the presence of
large quantities of aggregates (Sabine Suppmann, The Recombinant
Protein Production Facility of the Max-Planck Institute in Munich,
personal communication).Useof nativegels canbea simple solution
due to their low cost; however, these gels require laborious optimi-
zation for eachprotein andmany artifacts can affect theﬁnal results.
Table 2
General and environmental considerations during protein puriﬁcation steps.
Issues
General issues
Temperature Heat increases the kinetic energy (energy of motion) of the protein chain. Excessive motion can break relatively weak H-bonds, as well as electrostatic
and hydrophobic interactions. An increase in temperature accelerates chemical reactions such as oxidation and deamidation. Carrying out the
puriﬁcation process under low temperature conditions may reduce the tendency for aggregation
Time Aggregation is a nucleation, time-dependent growth process. A ‘‘quick strategy of puriﬁcation’’ must be designed to allow protein storage as soon as
possible
Protein concentration For prone-to-aggregate proteins, high protein concentrations in each of the puriﬁcation steps can start or speed up the nucleation aggregation process:
(1) Ratio lysis/cell
(2) Protein concentration during each step
(3) Overloading column
(4) High protein concentrations during elution
Stresses Freezing and thawing, exposure to air, interactions with metal surfaces, agitation, and additional mechanical or non-mechanical stresses might
increase the tendency to aggregate. Minimizing these stresses may reduce aggregation
Protein strategy Extended puriﬁcation procedures, and the presence of soluble aggregates may accelerate protein insolubility. This nucleation process can be
considerably avoided by early elimination of soluble aggregates (SEC or other chromatographic procedures like ion exchange or mixed mode
chromatography), and a quick strategy of selection of a puriﬁcation optimization procedure and arrangement of methods and columns
Protein environment
Buffer type, pH, and salt concentration Salt concentration: This can affect the aggregation of different proteins differently; reducing electrostatic interactions at high salt concentrations, or
increasing electrostatic interactions at low salt concentrations. These changes can cause either the stabilization or destabilization of proteins, or even
denaturation [71]
pH: pH can greatly affect the protein structure. It can change the electric charge of acidic or basic functional groups on the protein as well as disrupt or
create electrostatic interactions that will alter the protein structure. pH determines the electrostatic interactions through charge distribution on the
protein surface [72]
Stabilizing (Kosmotropic) agents.
Decrease aggregation by stabilizing the protein structure,
avoiding partial unfolding.
In some cases these agents can increase aggregation by enhancing
protein–protein associations [61]
Osmolytes (sugars, amino acids, polyols, etc.): Decrease aggregation by stabilizing the structure of water-water interactions, which causes water
molecules to favorably interact with macromolecules. This stabilizes intermolecular interactions [64,73–75
Kosmotropic salts: These salts have a higher salting-out effect according to the Hofmeister series. They act as a protein stabilizer (usually small ions, low
polarizability), and as polar water-structure makers
Detergents: Surfactants can stabilize proteins by two major mechanisms: (a) by settling at an interface, and preventing protein adsorption and
associated surface activity loss and/or surface-induced aggregation or (b) by binding to hydrophobic patches of proteins and thus preventing a close
approach and aggregation. Some surfactants may function according to only one of these mechanisms, whereas others may function according to both
[3]
Ligands, inhibitors, etc.: Can stabilize the protein structure
Aggregation destabilizing (Chaotropic) agents.
May destabilize aggregates formed by proteins in or near the
native state.
But in other cases they can cause partial denaturation and
consequently enhance aggregation [61]
H bonding agents (urea and GuHCl): For several proteins, low concentrations of these agents (up to 2 M) can destabilize aggregation by decreasing the
net hydrophobic effect of hydrophobic regions by disordering water molecules adjacent to the protein [71]Higher concentrations of these agents can
lead to unfolding of the protein chain by interfering with intra-molecular interactions mediated by non-covalent forces such as hydrogen bonds, van
der Waals forces, and hydrophobic effects
Arginine: The mode of interaction between Arginine (Arg) and protein [73] in is still under extensive investigation [73,76]. Arg as an aggregation
suppressor during refolding was ﬁrst reported in a patent application [77]; its stepwise reduction of denaturant concentrations in combination with the
addition of Arg is the most conventional method for protein refolding [78]. Like GdnHCl, Arg interacts in a similar manner with the amino acid side
chains and peptide backbones, suggesting that it has afﬁnity for side chain groups, most signiﬁcantly for aromatic side chains [76]. Arg is also a versatile
additive for protein formulation and afﬁnity column chromatography [71]
Reducing agents: Mild reductants and mild oxidants can lead to changes in protein conformation that may alter the function of the protein. Mild
reductants can break disulﬁde bonds and may lead to dissociation of parts of the protein chain(s) that are normally associated. Mild oxidants can cause
the formation of disulﬁde bonds and may lead to association of parts of the protein chain that are normally not associated. A problematic crossroad is a
mixture of free cysteines and disulﬁde bonds in the same protein. Our approach in this case is not to use reducing agents at all during this process, or at
least at a very low BME concentration (2 mM) as a compromise solution
Chaotropic salts: They have a higher ‘‘salting-in’’ effect according to the Hofmeister series. On one hand, they are water-structure breakers and protein
destabilizers; but on other hand, they can reduce protein–protein interactions by shielding charges and by preventing the stabilization of salt bridges
[61,64,79]
Detergents: Some detergents disrupt hydrophobic interactions
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Table 3
Additives Used to Stabilize Folding and to Prevent Aggregation Summary table of different publications [50,61–63,69,78–81] and from commercial websites (DILYX
Biotechnologies OptiSol protein solubility screening kit application manual, HAMPTON: Solubility and stability screen).
Additive Recommended initial concentration Recommended concentration range
Sugars and osmolytes
Glycerol 10% 0–40%
TMAO (trimethylamine N-oxide) 0.5 M 0–1 M
Glucose 0.5 M 0–2 M
Sucrose 0.5 M 0–1 M
Trehalose 0.5 M 0–1 M
Ethylene glycol 10% 0–60%
D-Sorbitol 0.5 M 0.2–1 M
Mannitol 2%
Xylitol 0.5 M 0.2–1 M
Glycine betaine 1 M
Amino acids and amino acid derivatives
Glycine 250 mM 0.5–2 M
Arginine L-HCl 125 mM 0–2 M
Arginine ethylester 250 mM 0–500 mM
Proline 250 mM 0–1 M
Potassium glutamate 250 mM 0–500 mM
Arginine L-HCl + L-glutamic acid (L-Glu) 50 mM each
Non-ionic detergents
Nonidet P40 (NP40) or Triton X-100 0.01% 0–1%
Tween 80 or 20 0.1% 0–1%
DDM: n-dodecyl b-D-maltoside 0.1% 0.01–0.5%
Brij 56: polyoxyethylene cetyl ether 0.05%
OG: Octyl glucoside (n-octyl-b-D-glucoside) 0.1% 0.01–0.5%
Zwiterionic detergents
NDSB: non-detergent sulfo betaine 0.5 M 0–1 M
CHAPS: 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate 0.1% 0.01–0.5%
Zwittergent 3–14 0.1% 0.001–0.2%
LDAO: lauryldimethylamine N-oxide 0.1% 0.01–0.5%
Ionic detergents
CTAB: cetyltrimethylammonium bromide 0.5%
Sarkosyl: sodium lauroyl sarcosinate 0.05% 0.01–0.5%
SDS: sodium dodecyl sulfate Up to 0.1%
Mild chaotrope agents and chaotrope salts
Urea 0.5 M 0–2 M
Guanidine HCl 0.5 M 0–2 M
N-Methylurea 250 mM Up to 2.5 M
N-Ethylurea 100 mM Up to 2 M
N-Methylformamide 3–15%
NaI 0.2 M 0–0.4 M
CaCl2 10–50 mM 0–0.2 M
MgCl2 10–50 mM 0–0.2 M
Mild and strong kosmotrope salts
NaCl (weak) 300 mM 0–1 M
KCl (weak) 200 mM 0–1 M
MgSO4 (strong) 100 mM 0–0.4 M
(NH4)2SO4 (strong) 50 mM 0–0.2 M
Na2SO4 (strong) 500 mM 0–0.2 M
Cs2SO4 (strong) 50 mM 0–0.2 M
Potassium citrate 100 mM
Citric acid 50 mM
Alcohols, polyols, polymers, polyamines, and others
Ethanol 5–10% Up to 25%
n-Penthanol 1–10 mM
n-Hexanol 0.1–10 mM
Cyclohexanol 0.01–10 mM
Polyethylene glycol (PEG 3350) 0.3–1.5% 0.1–0.4 g/L
Polyvinylpyrrolidone 40 (PVP40) 0.05–4%
Alpha-cyclodextrin 8–40 mM
Beta-cyclodextrin 1–5 mM
Putrescine, spermidine, and spermine 0.1 M
Formamide 0.1%
Reducing agents
b-Mercaptoethanol (BME) 2–5 mM 1–10 mM
Dithiothreitol (DTT) 1 mM 0.1–10 mM
Tris(2-carboxyethyl)phosphine (TCEP) 1–5 mM 1–50 mM
M. Lebendiker, T. Danieli / FEBS Letters 588 (2014) 236–246 243Size exclusion chromatography (SEC), despite its limitations, is
the most accepted and reliable technique to detect correctly oligo-
merized proteins. SEC can be coupled in-line to a light-scatteringdevice (SEC-MALS) to measure the absolute molar mass, size, and
shape of macromolecules in solution. One major disadvantage is
that it is time consuming, although this can be partially circum-
FINAL GOAL
Selecon of  opmal lysis condions: the least protein in pellets
Opmal IMAC condions: least protein in the unbound fracon and a higher eluon 
yield
Stable condions aer overnight incubaon: the best monomeric/soluble aggregaon 
rao
Smal-scale IMAC puriﬁcaon**
Analysis aer overnight incubaon at 4°C
1)  Visual selecon of non-turbid samples    2) PAGE-SDS analysis aer a short spin
3) Analycal SEC of the best condions
Second round of opmizaon: expand the screening of selected 
families of  addives or use a combinaon of families***
Final opmizaon step: minimize  the addive 
concentraon****
Inial step: Parallel bacterial lysis with diﬀerent families of  
addives*. 
Flow chart 2. Screening methodology showing the best additives for purifying
prone-to-aggregate proteins. ⁄Different families of additives were used to stabilize
folding and prevent aggregation during puriﬁcation, as can be seen in Table 3. As a
start screen we added additives to a 50 mM buffer (HEPES, TrisHCl, etc. pH 7.5–8.0)
with a relatively high NaCl concentration (0.5 M) and reducing agents according to
the presence of free Cys residues (see Table 2 and 3).  Control.  Non-ionic
detergent (0.5%).  Zwittergent (0.5%).  Osmolyte (0.5 M).  Urea or GuHCl (1 M). 
Add Arg only in the elution buffer (0.5 M). ⁄⁄Alternative strategy: Split puriﬁed
protein after IMAC puriﬁcation and dilute in buffers with different additives. ⁄⁄⁄Use
the same protocol as in ﬁrst round. Check similar or a combination (synergism) of
additives around the best condition obtained from the ﬁrst step (see Table 3).
⁄⁄⁄⁄Same protocol, using lower additive concentrations of the best results from
previous rounds. Alternative: Additive concentrations can be drastically reduced in
the later puriﬁcation steps without changing the additive concentration during lysis
and the capture step.
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backs are solubilization of reversible aggregates as a result of dilu-
tion effects, and the loss of larger aggregates in the pre-column
ﬁlters [67].
A popular method in crystallography or NMR studies is the ﬂuo-
rescence-based thermal shift (ThermoFluor) assay. It uses an envi-
ronmentally sensitive dye, Sypro Orange, to monitor the thermal
stability of a pure protein under different buffer conditions
[68,69]. Real-time PCR machines with a ﬂuorescent detector are
used to compare melting curve shifts in Tm (the midpoint of the
unfolding transition). However, this approach has some disadvan-
tages: it cannot provide information regarding the oligomeric state
of the protein, it cannot be used in the presence of additives such
as detergents, and the presence of intrinsic ﬂuorescent aggregates
makes it difﬁcult to interpret. Moreover, the ability to predict best
crystallization conditions is still under debate within the protein-
producing community.
Choosing the analysis approach should take into account the
large number of tested variables (different buffers, pH, additives,
salt, etc.) and the fact that no single method is optimal for identi-
fying all types of aggregates. Unfortunately, approaches that pro-
vide the most accurate information regarding the oligomeric
state of the protein are not applicable in high-throughput screen-
ing (HTS).
Our approach is to combine a fast standard SDS–PAGE analysis
that allows screening of many variables, with analytic SEC, that
provides information regarding the oligomeric conformation of
the protein. SDS-PAGE allows the easy selection of the most prom-
ising condition and considerably eliminates the number of samples
to be analyzed by SEC.
3.4. Our comprehensive approach for optimizing solubility during
puriﬁcation
In standard procedures, puriﬁed or partially puriﬁed protein is
used to screen the solubility conditions. We have found that solu-
bility problems at the puriﬁcation level should be tackled as early
as the cell-lysate step. Starting the screen at this initial step, fol-
lowed by analyzing the oligomeric state of partially puriﬁed pro-
tein at different puriﬁcation steps provides maximum
information on solubility issues and improves the ﬁnal output,
since it may rescue the protein fraction that was partially insoluble
in the bacteria and that was mistakenly considered as inclusion
bodies [63].
Our screening consists of a short list of solubility-promoting
additives during cell lysis (Flow chart 2), followed by a quick par-
allel capture step of small-scale IMAC puriﬁcation (or any other
capture method) in the presence of selected additives. Samples
are then analyzed on PAGE–SDS and include insoluble lysis ex-
tracts, unbound fractions, and eluted protein. Incubation of the
eluted protein at 4 C for 16 h will allow the detection of slow-
forming aggregates. Samples that do not contain aggregates (based
on the initial visual detection of turbidity and then based on PAGE–
SDS analysis) will be selected for further testing on analytical SEC,
searching for the best monomer/soluble aggregate ratio.
From this ﬁrst screening, we obtain valuable information
regarding: (a) the effect of representative additive groups on opti-
mal lysis, (b) better binding to the capture resin, and (c) the best
yield of native oligomeric conformation over time.
A short alternative method is to split a common eluate after
IMAC puriﬁcation, and dilute it in buffers with different additives.
Its drawback is that in this way only data regarding protein stabil-
ity are obtained, and important information on lysis yield and resin
capture is lost.
We therefore prefer to check, using this ﬁrst screen, a non-ionic
and a zwiterionic detergent, a mild chaotrope, an osmolyte, andArginine (only in the elution buffer), all of which are in the same
relatively high salt buffer. Deliberately, we prefer not to introduce
pH as a variable in this ﬁrst screening because: (1) IMAC binding
itself constrains pH options, (2) we try to reduce as much as possi-
ble the number of variables to check, and we consider that pH is
less important at this point, and (3) there is indirect evidence from
refolding screens that buffers with pH far away from the protein’s
pI, are best for protein refolding [70]. We prefer to use pH screen-
ings at later puriﬁcation stages and storage conditions.
Next, the optimization rounds check whether additives from
the same family yield even better results (Table 3). This step can
be improved by combining additives from different families in or-
der to obtain a synergistic effect. In the ﬁnal round, the additives’
concentration is optimized. This last optimization is very impor-
tant when additive concentration use in the capture step is not
compatible with the next steps of puriﬁcation or with protein
application. We employ this strategy in most of the projects that
involve protein production in bacteria, with high success rates in
dozens of cases. A few successful examples can be found in the fol-
lowing references [25–27,57–59].
Optionally, a drastic dilution of additive concentration at later
stages of puriﬁcation can be considered, since the beneﬁcial effects
of the chosen additives are most signiﬁcant at the cell lysis and
early puriﬁcation steps, and the additive concentration can be con-
siderably reduced in the later puriﬁcation steps [63].
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cell-lysis stage and capture steps does not necessarily match the
protein’s requirements for ensuring the next chromatographic
steps, the optimal storage conditions, or for protein concentrations
for structural studies and other downstream applications.
4. Conclusions
In an academic research environment it is very tempting to
avoid extensive and laborious screening when dealing with protein
solubility problems. HTS platforms that allow parallel screening of
multiple parameters are not commonly available in most laborato-
ries. Many researchers use available vectors and strains in their
surroundings, adopt standard buffer conditions at the puriﬁcation
step and end up dealing with aggregation problems at the end of
the whole production process. Moreover, individual parameters
in the process are frequently being tested in a linear process,
changing a single parameter at a time. This time-consuming, and
often frustrating approach can lead to a dead end due to the forma-
tion of protein aggregates. In this review we described a variety of
expression and puriﬁcation tools used to increase the efﬁciency of
producing soluble proteins. Most importantly, we tried to provide a
simple and modular toolbox for designing a minimized expression
and puriﬁcation screen. We believe that following these hierarchic
rules will make soluble protein production in E. coli-based systems
more efﬁcient, simpler, and less costly. Moreover, the rules for
designing this screen can be applied to the HTS formats, as well.
In the ‘protein expression’ section we focused on the pros and
cons of the initial cloning steps, the possible fusion partners, suit-
able bacterial hosts, and the optimal induction conditions. The
most beneﬁcial approaches were then combined to form a mini-
mized hierarchical screening platform, where the main goal is to
obtain maximal yield of the correct oligomeric conformation along
with the minimal presence of insoluble proteins, or soluble aggre-
gates, in the shortest possible time. Although obtaining soluble
proteins during the expression steps is an essential prerequisite
for the subsequent puriﬁcation steps, aggregation can also occur
at later stages, e.g., during the puriﬁcation process. In the ‘protein
puriﬁcation’ section we describe in detail: (1) the factors that can
affect solubility during the puriﬁcation step, (2) general and envi-
ronmental considerations that can affect protein puriﬁcation, and
(3) various methods for monitoring protein aggregation and their
limitations. Finally, we describe our approach for screening the
best additives and the conditions needed for purifying prone-to-
aggregate proteins.
Despite the constant ﬂow of new and improved vectors, host
strains, HTS platforms, various buffer formulations, additives and
other factors, the experience accumulated at our core facilities
indicates that combining traditional strategies for screening paral-
lel factors, both in the expression and the puriﬁcation steps, results
in a synergistic effect, thus allowing increased production efﬁcacy
of soluble proteins using the simple tools readily available in most
research laboratories. We believe that our integrated and hierar-
chical approach follows the ‘‘20/80 rule’’, achieving 80% of the ben-
eﬁts with only 20% of the resources, while addressing the vast
majority of solubility problems. Finally, we believe that this ap-
proach simpliﬁes the decision whether to continue to invest in
E. coli production or instead to explore the potential of using other
hosts.
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